文献速递核素与放射性配体治疗放射性药物与辐射防护

肽受体放射性核素治疗中改变治疗方案的血液学毒性风险及其与骨髓剂量的关系

Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy.
PubMed 文献 · EJNMMI Res · 2024-02-06

该研究基于59例患者229次177Lu-DOTATATE治疗,用SPECT/CT图像剂量学估算骨髓吸收剂量,分析其预测改变治疗方案的血液学毒性的潜力。骨髓平均吸收剂量为每次治疗0.42 Gy,白细胞、中性粒细胞和血红蛋白浓度与剂量存在剂量-反应关系,但无骨髓剂量学参数能明确预测治疗相关毒性;有骨骼转移的患者发生改变治疗方案的毒性风险更高(比值比=6.0)。

要点

  • 每次治疗骨髓平均吸收剂量为0.42 Gy(中位数0.33 Gy,标准差0.27 Gy)。
  • 白细胞、中性粒细胞和血红蛋白的剂量-反应关系在每次治疗后31-45天最明显。
  • 有骨骼转移的患者发生改变治疗方案的毒性风险更高(比值比=6.0)。

核心结论

  • 肽受体放射性核素治疗中改变治疗方案的血液学毒性相对罕见,且似乎难以完全通过治疗后图像剂量学预测。
  • 对于有骨骼转移的患者,血液学剂量-反应关系更强。
  • 未来研究可能聚焦于该患者群体,以进一步探究剂量学在预测血值下降方面的 usefulness。

研究设计与样本

  • 研究分析了59例患者229次177Lu-DOTATATE治疗前后采集的外周血样本。
  • 共940次采血 occasions 提供白细胞、中性粒细胞、血小板、红细胞和血红蛋白浓度数据。
  • 每次治疗后2或3个时间点采集SPECT/CT图像数据,由无转移腰椎椎体的放射性浓度计算骨髓吸收剂量;根据病历分析延迟和终止治疗的发生率。

主要发现

  • 每次治疗骨髓平均吸收剂量为0.42 Gy(中位数0.33 Gy,标准差0.27 Gy)。
  • 观察到白细胞、中性粒细胞和血红蛋白浓度与骨髓剂量之间的剂量-反应关系,在每次治疗后31-45天最明显。
  • 有骨骼转移的患者中上述相关性更强。
  • 血液学毒性相关延迟治疗和终止治疗的发生率分别为6%和12%。
  • 所研究的骨髓剂量学参数均不能明确预测治疗相关毒性;有骨骼转移的患者发生改变治疗方案的毒性风险更高(比值比=6.0)。

关键数值与推荐

  • 骨髓吸收剂量由无转移腰椎椎体的放射性浓度计算。
  • 每次治疗骨髓平均吸收剂量为0.42 Gy(中位数0.33 Gy,标准差0.27 Gy)。
  • 血液学毒性相关延迟治疗率为6%,终止治疗率为12%。
  • 有骨骼转移的患者发生改变治疗方案的毒性风险的比值比为6.0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peptide receptor radionuclide therapy is effective in treating neuroendocrine tumours, but treatment may be limited by kidney and bone marrow toxicity. In this work, the absorbed dose burden to the bone marrow was estimated using image-based dosimetry and its potential use for predicting treatment-altering toxicity was studied. Peripheral blood samples taken before and after 229 treatments with 177Lu-DOTATATE in 59 patients were studied. In connection to the treatments, a total of 940 blood sample occasions provided data on white blood cell, neutrophil granulocyte, platelet, erythrocyte and haemoglobin concentrations. SPECT/CT image data were collected at two or three time points after each treatment. Absorbed doses to bone marrow were calculated from the activity concentration in a metastasis-free lumbar vertebra. The rate of delayed and aborted treatments was analysed based on medical records. RESULTS: The average absorbed dose to the bone marrow was 0.42 Gy (median 0.33 Gy, SD 0.27 Gy) per treatment. Dose-response relationships between white blood cells, neutrophil granulocytes and haemoglobin concentrations were observed, most prominently at 31-45 days after each treatment. The correlations were stronger in patients with skeletal metastases. The rates of haematological toxicity-related delays and aborted treatments were 6% and 12%, respectively. None of the studied bone marrow dosimetric parameters could clearly predict treatment-related toxicity. However, patients with skeletal metastases had higher risk of treatment-altering toxicity (odds ratio = 6.0). CONCLUSIONS: Treatment-altering haematological toxicity in peptide receptor radionuclide therapy is relatively rare and appears difficult to fully predict from post-therapeutic image-based dosimetry. However, for patients with skeletal metastases, the haematological dose-response relationships are stronger. Future studies may focus on this patient group, to further investigate the usefulness of dosimetry in predicting decreases in blood values.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Persson M, Hindorf C, Ardenfors O, et al. Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy. EJNMMI Res. 2024. PMID: 38319478. doi:10.1186/s13550-024-01077-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。